T3D
0.05
233.3%
PEN
0.33
-46.8%
GML
0.045
60.7%
RGL
0.003
-40%
ENT
0.008
60%
KLR
0.54
-34.1%
AIV
0.02
53.8%
JAV
0.002
-33.3%
QXR
0.006
50%
M2R
0.002
-33.3%
AQI
0.038
35.7%
RDS
0.004
-33.3%
NPM
0.018
28.6%
AOA
0.003
-25%
AHK
0.455
28.2%
BLZ
0.003
-25%
VML
0.165
26.9%
MEM
0.003
-25%
FIN
0.005
25%
LEG
0.007
-22.2%
VRC
0.005
25%
ADG
0.004
-20%
BCM
0.023
21.1%
CAV
0.004
-20%
FL1
0.12
20%
CVB
0.14
-20%
WHK
0.012
20%
FBR
0.004
-20%
S66
0.195
18.2%
IMI
0.008
-20%
KLS
4.76
18.1%
TRM
0.042
-19.2%
PAT
0.04
17.6%
GBE
0.06
-16.7%
NXL
2.41
17%
XGL
0.02
-16.7%
AJX
0.007
16.7%
ATV
0.016
-15.8%
AVE
0.007
16.7%
LU7
0.011
-15.4%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AGN on track for Phase 2 trials during CY24

Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts